






Viet Nam COVID-19 Situation Report #110

Epidemiological report as of 30 September 2023, 18:00

Situation Summary

Cumulative numbers from 25 Jan 2020 – 30 September 2023

 11,623,698 Cases (63/63 provinces)	 10,640,809 (91.5%) Recovered	 43,206 (PFC 0.4%) Deaths	 ~46 M Lab. Tests	 266,532,868 Vaccine doses administered
---	---	---	---	--

Highlights from the current situation (from 27 April 2021 to 30 September 2023)¹

- A total of 11,090 new cases and no deaths were reported from 1 June to 30 September 2023. Compared to the previous four months (86,111 cases and no deaths), the number of new cases decreased more than 7.7 times.
- **Cumulatively** from April 2021 to 30 September 2023, a total of **11,623,698 cases** have been reported including **43,206 deaths** (PFC 0.4%) from 63 cities/provinces. [See Figures 1 and 2.](#)
- Five (5) cities/ provinces with highest cumulative case number reported include: Ha Noi (1,649,227 cases, 1,238 deaths, PFC 0.08%); HCMC (628,468 cases, 20,476 deaths, PFC 3.31%); Hai Phong (538,352 cases, 138 deaths, PFC 0.03%), Nghe An (502,520 cases, 145 deaths, PFC 0.03%) and Bac Giang (391,361 cases, 93 deaths, PFC 0.02%).
- The **Omicron** variant of concern (**VOC**) **accounts for 83.7%** among the sequences uploaded from Viet Nam into the global reporting platform (GISAID) since it was first reported in country in December 2021 (6,411 out of 7,655 sequences).
- In light of the WHO's announcement on May 5th that COVID-19 no longer constitutes a Public Health Emergency of International Concern (PHEIC), the Viet Nam Ministry of Health (MoH) has developed a plan for a long-term sustained management of COVID-19, period from 2023 to 2025, to be approved by the MOH leaders. This plan is drawn upon the WHO's Strategic Preparedness and Response Plan for 2023-2025 as well as the contextual recommendations provided by WHO Viet Nam.
- Viet Nam is encouraged to continue implementing multisource surveillance especially using trends in hospital admissions for severe and critical cases, reports of deaths and EBS as the country is moving forward to a long term sustained COVID-19 management.

¹ For updates before 1 April 2023, refer to previous Sitreps. While epidemiological figures are as of 31 May 2023, other information may cover beyond this cut-off date.




Figure 1. Epidemic curve of COVID-19 laboratory confirmed cases and deaths by week of reporting for the current outbreaks, from 27 Apr 2021 – 30 Sep 2023, Viet Nam²




Figure 2a. Distribution of COVID-19 cumulative confirmed cases by province, 27 Apr 2021 – 30 Sep 2023, Viet Nam




Figure 2b. Distribution of COVID-19 cumulative deaths by province, 27 Apr 2021 – 30 Sep 2023, Viet Nam

² Figures excluded the most recent backlogs of cases reported.

Age and sex distribution of COVID-19 cases: Analysis from 10,411,698 cases shows that ages of cases range from 2 months to 100 years old. About 48.7% of all cases are in the 30-69 years old age group, 3.9% are above 70 years old, and the remaining 47.4% are under 30 years old. The proportion of male and female remains at 45.2% vs 54.8%, respectively.

For more details, visit: [COVID-19 Dashboard](#) of the General Department of Preventive Medicine (GDPM)/MOH.

Cumulatively from Jan 2020 to 30 September 2023, Viet Nam has reported a total of **11,623,698 laboratory confirmed cases** from all 63 provinces including **43,206 deaths (PFC 0.4%)**.

❖ **Vaccine supply and vaccination** (See Annex 1)

- As of 30 September 2023, a total of **263,253,798 doses of COVID-19 vaccines have arrived in Viet Nam**. In which: COVAX: 71,078,942 doses; donation from countries: 56,352,000 doses; and bilateral procurement: 135,822,856 doses.
- As of 30 September 2023, a total of **266,532,868 doses have been administered** (about 100,000 doses administered in the last 4 months, but none were administered since August 2023): 90,277,455 people from 5 years and above got **first dose (92.0% of total population)** and number of people from 5 years and above completed **second dose** has reached 85,967,837 (**87.6% of total population**). There are 12,852,504 immunocompromised people and high-risk people got additional dose and **57,985,275 people** who are **fully vaccinated and got initial booster dose (59.1% of total population)** or 72.2% of target population from 12 years old and above). There are 17,958,059 people got **second booster dose (18.3% of total population)**.
- As of 30 September 2023, a total of 9,130,889 adolescents **12-17 years of age got first dose (~100%)** and 9,021,382 **got full doses (~100%)**. **66.3%** of this age group (5,813,384 adolescents) got initial booster dose.
- As of 30 September 2023, 10,236,628 children **5-11 years old** vaccinated with **first dose (86.3% of targeted children)** and 8,488,652 children get **full dose (71.6% of targeted children)**.
- To date, nine vaccines in Emergency Use Authorization by NRA of Viet Nam: AstraZeneca, Pfizer, Moderna, Johnson & Johnson (Janssen), Sinopharm BIBP, Sputnik V, and Hayat-Vax COVID-19 (Sinopharm manufacturing site), Abdala and Covaxin (produced by Bharat Biotech International Limited, India).
- [From 25-29 September 2023, Strategic Advisory Group of Experts \(SAGE\) met to review the epidemiology of COVID-19, including death rates among priority-use groups, vaccine effectiveness data during Omicron XBB sub lineages circulation; and pre-clinical and clinical data on novel monovalent XBB vaccines. Based on the data reviewed, SAGE recommended a simplified single-dose regime for primary immunization for most COVID-19 vaccines which would improve acceptance and uptake and provide adequate protection at a time when most people have had at least one prior infection. SAGE approved an updated roadmap for COVID-19 vaccination that reflects the simplified schedule, updated recommendations on revaccination. The updated roadmap will be shared shortly once available.](#)

❖ **Government direction and key public health and social measures (PHSM)**

- **20 June 2023** – The MOH promulgated a Decision on Guidelines for Prevention and Control COVID-19 at health care facilities, the guidelines replaced the Guidelines which was issued on 30 August 2022 [[EBS](#)].
- **18 August 2023** – The Government issued a Resolution on transferring drugs, supplies and biological products purchased from and biological products that have been purchased from the state budget for COVID-19 outbreak prevention and control but have not yet been used for examination and treatment other diseases [[EBS](#)].
- **22 September 2023** – The MOH submitted the documentation dossier to the Government to officially reclassify COVID-19 from Class A to Class B infectious disease under the current Law of Prevention and Control of Infectious Diseases, following the PM's decision at the 20th National Steering Committee (NSC) meeting. Additionally, the MOH proposed the abolishment of specific documents associated with COVID-19 prevention and control, which were issued by the NSC.

❖ Laboratory testing

- As of 30 Sep 2023, approximately 46 million RT-PCR tests (both single and pooled samples) have been conducted since Jan 2020. For the current outbreak, approx. more than 40.1 million RT-PCR tests (both single and pooled samples) have been conducted.
- **Whole Genome Sequencing:** As of 30th September 2023, Viet Nam has uploaded a total of 9,818 SARS-CoV-2 sequences to the GISAID platform (since the beginning of the pandemic), 444 additional sequences have been uploaded for the last four months (from June to September). Of the 7,655 sequences uploaded from 24 Dec 2021 to 30th September 2023, 6,411 sequences (83.7%) were Omicron.
- Currently, there are 403 confirmatory laboratories for COVID-19 by RT-PCR established in country (167 from Northern region, 40 from Central-coastal region, 9 from Central-highland region, and 187 from Southern region).

❖ Case management

- As of 30th September 2023, **38 COVID-19 cases** were being isolated, monitored, or treated in the country. Of those, **1 severe case requiring oxygen**, and no cases under invasive ventilation or ECMO. ([Source](#)). For the past three months, the number of reported COVID-19 severe cases requiring oxygen nationwide has consistently remained below ten.

❖ Risk communication

- Although WHO declared an end to COVID-19 as a Public Health Emergency of International Concern on 5 May 2023, COVID-19 continues to circulate in Viet Nam, including Omicron sub-variants. As part of the long-term sustained management approach to COVID-19 in Viet Nam, WHO Viet Nam continues to encourage the community to follow MOH 2K+ guidelines for adults and children. This includes a particular emphasis on mask wearing in crowded places and enclosed spaces, regular hand washing and maintaining protection against severe illness and death with COVID-19 vaccines, especially for high-risk and vulnerable groups to get their recommended booster doses according to schedule. Updated guidance to the public from MOH and WHO are available through multiple channels, including on the MOH Facebook page: [VNM MOH Sức khỏe Việt Nam](#) and the WHO Facebook page: [World Health Organization Viet Nam](#).


WHO's support

Based on the 4th iteration of the [Strategic Preparedness and Response plan for 2023-2025](#), published by WHO on 3rd May 2023, WCO provided technical advice and support to the MOH in the ongoing development of the national plan for a long-term sustained management of COVID-19. This includes recommendations and specific considerations for Viet Nam moving forward as COVID-19 no longer constitutes a PHEIC. References and technical advice were also provided to facilitate the Government's decision on reclassifying COVID-19 from a disease group A to group B.


WCO team continues to facilitate the consultation process with MSs in the development of a new Asia Pacific Health Security Action Framework (AP-HSAF), taking the lessons learned from COVID-19 response. This HSAF is expected to be endorsed during the 74th Regional Committee Meeting (RCM) which will take place from 16 – 20 October 2023 in Manila, the Philippines.

ANNEX 1 – COVID-19 vaccines supply and deployment as of 30 September 2023

Vaccine by source (received)



Vaccine by product (received)



Progress of vaccine usage and primary vaccination coverages per total population, as of 30 September 2023

